Nature Communications (Feb 2022)
Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer
- I.-M. Launonen,
- N. Lyytikäinen,
- J. Casado,
- E. A. Anttila,
- A. Szabó,
- U.-M. Haltia,
- C. A. Jacobson,
- J. R. Lin,
- Z. Maliga,
- B. E. Howitt,
- K. C. Strickland,
- S. Santagata,
- K. Elias,
- A. D. D’Andrea,
- P. A. Konstantinopoulos,
- P. K. Sorger,
- A. Färkkilä
Affiliations
- I.-M. Launonen
- Research Program in Systems Oncology, University of Helsinki
- N. Lyytikäinen
- Research Program in Systems Oncology, University of Helsinki
- J. Casado
- Research Program in Systems Oncology, University of Helsinki
- E. A. Anttila
- Research Program in Systems Oncology, University of Helsinki
- A. Szabó
- Research Program in Systems Oncology, University of Helsinki
- U.-M. Haltia
- Research Program in Systems Oncology, University of Helsinki
- C. A. Jacobson
- Laboratory of Systems Pharmacology, Harvard Medical School
- J. R. Lin
- Laboratory of Systems Pharmacology, Harvard Medical School
- Z. Maliga
- Laboratory of Systems Pharmacology, Harvard Medical School
- B. E. Howitt
- Department of Pathology, Stanford University School of Medicine
- K. C. Strickland
- Department of Pathology, Duke University Medical Center
- S. Santagata
- Laboratory of Systems Pharmacology, Harvard Medical School
- K. Elias
- Department of Obstetrics and Gynecology and Reproductive Biology, Brigham and Women’s Hospital
- A. D. D’Andrea
- Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School
- P. A. Konstantinopoulos
- Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School
- P. K. Sorger
- Laboratory of Systems Pharmacology, Harvard Medical School
- A. Färkkilä
- Research Program in Systems Oncology, University of Helsinki
- DOI
- https://doi.org/10.1038/s41467-022-28389-3
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 14
Abstract
The tumour microenvironment has not been fully characterised in high-grade serous ovarian cancers (HGSOC). Here, the authors use highly multiplexed imaging to analyse the HGSOC immune microenvironment at spatial and single-cell resolution, with clinically relevant findings for BRCA1/2-mutated tumours.
